Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy
C Cruz-Teran, K Tiruthani, M McSweeney, A Ma… - Advanced drug delivery …, 2021 - Elsevier
To address the COVID-19 pandemic, there has been an unprecedented global effort to
advance potent neutralizing mAbs against SARS-CoV-2 as therapeutics. However, historical …
advance potent neutralizing mAbs against SARS-CoV-2 as therapeutics. However, historical …
[HTML][HTML] Pandemic preparedness: developing vaccines and therapeutic antibodies for COVID-19
GD Sempowski, KO Saunders, P Acharya, KJ Wiehe… - Cell, 2020 - cell.com
The SARS-CoV-2 pandemic that causes COVID-19 respiratory syndrome has caused global
public health and economic crises, necessitating rapid development of vaccines and …
public health and economic crises, necessitating rapid development of vaccines and …
Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite
Numerous antibodies that neutralize SARS-CoV-2 have been identified, and these generally
target either the receptor-binding domain (RBD) or the N-terminal domain (NTD) of the viral …
target either the receptor-binding domain (RBD) or the N-terminal domain (NTD) of the viral …
Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology
Analysis of the specificity and kinetics of neutralizing antibodies (nAbs) elicited by SARS-
CoV-2 infection is crucial for understanding immune protection and identifying targets for …
CoV-2 infection is crucial for understanding immune protection and identifying targets for …
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future
protection of individuals and populations against SARS-CoV-2. Moreover, passively …
protection of individuals and populations against SARS-CoV-2. Moreover, passively …
[HTML][HTML] Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding
The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein mediates viral
attachment to ACE2 receptor and is a major determinant of host range and a dominant target …
attachment to ACE2 receptor and is a major determinant of host range and a dominant target …
[HTML][HTML] Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19
T Sekine, A Perez-Potti, O Rivera-Ballesteros, K Strålin… - Cell, 2020 - cell.com
Summary SARS-CoV-2-specific memory T cells will likely prove critical for long-term immune
protection against COVID-19. Here, we systematically mapped the functional and …
protection against COVID-19. Here, we systematically mapped the functional and …
[HTML][HTML] Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies
CO Barnes, AP West, KE Huey-Tubman… - Cell, 2020 - cell.com
Neutralizing antibody responses to coronaviruses mainly target the receptor-binding domain
(RBD) of the trimeric spike. Here, we characterized polyclonal immunoglobulin Gs (IgGs) …
(RBD) of the trimeric spike. Here, we characterized polyclonal immunoglobulin Gs (IgGs) …
Cryo-EM structures of SARS-CoV-2 spike without and with ACE2 reveal a pH-dependent switch to mediate endosomal positioning of receptor-binding domains
The SARS-CoV-2 spike employs mobile receptor-binding domains (RBDs) to engage the
human ACE2 receptor and to facilitate virus entry, which can occur through low-pH …
human ACE2 receptor and to facilitate virus entry, which can occur through low-pH …
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
Summary The SARS-CoV-2 spike (S) glycoprotein contains an immunodominant receptor-
binding domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient …
binding domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient …